Company Filing History:
1 out of 38 
1 out of 111 Years Active: 1999-2002
Title: Joseph Schlessinger: A Pioneer in Fibroblast Growth Factor Research
Introduction
Joseph Schlessinger is a notable inventor based in Wayne, PA (US), recognized for his significant contributions to the field of molecular biology. He holds 2 patents that focus on the cloning and characterization of fibroblast growth factor receptors. His work has paved the way for advancements in understanding growth factor interactions and their implications in drug development.
Latest Patents
Schlessinger's latest patents include groundbreaking research on fibroblast growth factor receptors. The complete cDNA cloning of two human genes, previously designated flg and bek, is disclosed in his patents. These genes encode for two similar but distinct surface receptors that consist of an extracellular domain with three immunoglobulin-like regions, a single transmembrane domain, and a cytoplasmic portion containing a tyrosine kinase domain with a typical kinase insert. The expression of these two cDNAs in transfected NIH-3T3 cells resulted in the biosynthesis of proteins of 150 kDa and 135 kDa for flg and bek, respectively. Direct binding experiments with radiolabeled acidic FGF (aFGF), basic FGF (bFGF), or kFGF inhibition of binding with native growth factors, along with Scatchard analysis of the binding data, indicated that bek and flg bind aFGF, bFGF, or kFGF with dissociation constants of (2-15)×10-11 M. This high-affinity binding of three distinct growth factors to each of the two different receptors represents a unique double redundancy without precedence among polypeptide growth factor/receptor interactions. The use of transformed host cells overexpressing flg or bek, or biologically active fragments thereof, for drug screening is also disclosed.
Career Highlights
Throughout his career, Joseph Schlessinger has worked with prominent companies such as Rhone-Poulenc Rorer and Rhone-Poulenc Rorer Pharmaceuticals Inc. His research has significantly impacted the understanding of growth factor signaling pathways and their therapeutic potential.
Collaborations
Some of his notable coworkers include Craig A. Dionne and Gregg B. Crumley. Their collaborative efforts have contributed to the advancement of research in the field of fibroblast growth factors.
Conclusion
Joseph Schlessinger's